Sun Yat-sen University: all 1,680 studies

Page 2 of 17. Open to participants first (609), then studies with results posted, then the rest; newest registration first within each.

• Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic CancerNot yet recruitingNCT07469956Phase 2
• Construction and Evaluation of a Flipped Discharge Model for Stomates With Colorectal CancerNot yet recruitingNCT07463690Not applicable
• Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingNCT07463677Phase 2
• Theory-Based Parenting Intervention for Preschool Children's Health BehaviorsRecruitingNCT07458009Not applicable
• An AI Educational Agent for Medical Machine Learning CoursesRecruitingNCT07449182Not applicable
• Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal CancerRecruitingNCT07448142Phase 2
• Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCLNot yet recruitingNCT07415980Phase 1/2
• Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled TrialNot yet recruitingNCT07413146Not applicable
• Multi-modal Fusion Model and Deep Learning for Predicting Treatment Response in NKTCLNot yet recruitingNCT07409168
• Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal CancerNot yet recruitingNCT07405736Phase 2
• Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in Resectable Locally Advanced Oral and HPV-unrelated Oropharyngeal Squamous Cell CarcinomaNot yet recruitingNCT07402538Phase 3
• Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II StudyNot yet recruitingNCT07398638Phase 1/2
• A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal CarcinomaRecruitingNCT07392320Phase 2
• Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCCRecruitingNCT07389629Phase 2
• Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal CarcinomaNot yet recruitingNCT07388758Phase 2
• Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCCRecruitingNCT07386158Phase 2
• Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal CarcinomaNot yet recruitingNCT07385079Phase 3
• QL1706 Plus Lenvatinib in Previously Treated Penile CancerRecruitingNCT07384416Phase 2
• SBRT Versus Surgical Resection for Small HCCRecruitingNCT07381660Phase 3
• FMD and Neoadjuvant Chemo-immunotherapy in TNBCRecruitingNCT07378306Phase 2
• Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal CarcinomaNot yet recruitingNCT07373990Phase 3
• Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III TrialNot yet recruitingNCT07371897Phase 3
• Magnetic Tracking and ECG-Guided Tip Confirmation System for PICCsRecruitingNCT07369427
• Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal CarcinomaRecruitingNCT07362979Phase 2
• A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT07354984Phase 2
• FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic CholangiocarcinomaNot yet recruitingNCT07353827Phase 2
• Prospective Geometric Analysis of Ultra-Widefield OCTA Characteristics in Central Serous Chorioretinopathy PatientsNot yet recruitingNCT07347119
• A Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Second-Line and Subsequent Treatments for Advanced Thymic Epithelial TumorsNot yet recruitingNCT07343453Phase 2
• TCR-T Cell Therapy for KRAS Mutation in Advanced Solid TumorsNot yet recruitingNCT07342738Early Phase 1
• EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell LymphomasNot yet recruitingNCT07339527Phase 1/2
• Selective Total Mesorectal Excision Based on Intra-Operative Frozen Section From Local Excision in Rectal Cancer Undergoing Neoadjuvant ChemoradiotherapyRecruitingNCT07337811Not applicable
• Paclitaxel Polymersomes + Carboplatin + Adebelimab: Neoadjuvant Phase Ⅱ Single-Arm Study for Resectable Mucosal MelanomaRecruitingNCT07336979Phase 2
• A Study of Hetrombopag Combined With rhTPO in the Treatment of Cancer Therapy-induced Thrombocytopenia (CTIT) in Solid Tumor Patients.Not yet recruitingNCT07334093Phase 2
• PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPCRecruitingNCT07332247Phase 2
• The Cold Ischemia Robot-assisted Partial NephrectomyRecruitingNCT07326280Not applicable
• LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPCRecruitingNCT07325539Phase 2
• Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular CarcinomaRecruitingNCT07324824Phase 2
• Effect of Intrathecal Morphine on Quality of Recovery After Laparoscopic Gynecological SurgeryNot yet recruitingNCT07322029Not applicable
• Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.Not yet recruitingNCT07320963Phase 1/2
• ArcFlex Sheath in TAVR TrialNot yet recruitingNCT07320274Not applicable
• Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral LiquidRecruitingNCT07311772Phase 3
• Postoperative Hypoxemia Increases the Risk of Anastomotic Leak After Radical EsophagectomyRecruitingNCT07309991
• A Prospective Multicenter Clinical Study of SCCG Protocol and ctDNA 5hmc in Predicting the Chemotherapy Sensitivity and Monitoring the Recurrence and Metastasis of Hepatoblastoma in Children and AdolescentsRecruitingNCT07300449Phase 2
• SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal CancerNot yet recruitingNCT07297030Phase 2
• Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLCNot yet recruitingNCT07294261Phase 2
• PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal CancerNot yet recruitingNCT07277842Phase 3
• A Phase I Study of WTX212A Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid TumorsRecruitingNCT07269899Phase 1
• Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority TrialNot yet recruitingNCT07261709Phase 2
• Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 InhibitorsRecruitingNCT07258108Phase 2
• Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)Not yet recruitingNCT07255612Phase 2
• A Study of Tumor-Agnostic MRD Detection in Stage III Colorectal CancerNot yet recruitingNCT07254156
• TAF Monotherapy Versus ETV Combined With TAF on the Efficacy and Prognosis of Immunotherapy for Hepatitis B-Related Hepatocellular CarcinomaNot yet recruitingNCT07253220Not applicable
• Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)RecruitingNCT07241793Phase 2
• Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI TreatmentRecruitingNCT07238881Phase 2
• Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal CarcinomaNot yet recruitingNCT07238569Phase 3
• A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast CancerNot yet recruitingNCT07235618Phase 2
• PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPCRecruitingNCT07235319Phase 3
• Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLCNot yet recruitingNCT07231575Phase 2
• The IVO-LUNG StudyNot yet recruitingNCT07204548Phase 2
• Risk Factors Affecting MSC Efficacy in ACLF PatientsRecruitingNCT07198854
• TEER In dynaMic sEvere Functional Mitral Regurgitation (TIMER)Not yet recruitingNCT07197021Not applicable
• IP rmhTNF-NC + Tislelizumab + Palliat RT for GIT Tumor Malignant Ascites After Failed Std TxNot yet recruitingNCT07196540Phase 2
• Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & BevacizumabRecruitingNCT07192185Phase 2
• Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma in ChildrenRecruitingNCT07188311Not applicable
• A Cohort Study on Cardiovascular and Cerebrovascular OutcomesEnrolling by invitationNCT07178015
• Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCCRecruitingNCT07177794Phase 3
• QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal CancerNot yet recruitingNCT07175636Phase 2
• Fruquintinib Combined With Standard Chemotherapy Versus Standard Chemotherapy as First-line Treatment for Advanced pMMR Endometrial CancerNot yet recruitingNCT07170982Phase 2
• Nintedanib for Improving Reproductive Outcomes in AdenomyosisNot yet recruitingNCT07162961Phase 3
• Risk Assessment for HBV-Related Liver CancerRecruitingNCT07160946
• Adaptive Immunotherapy for Nasopharyngeal CarcinomaRecruitingNCT07154069Phase 3
• Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal CancerRecruitingNCT07150247Phase 2
• Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull BaseNot yet recruitingNCT07145931Phase 2
• MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G/GEJ AdenocarcinomaNot yet recruitingNCT07144995
• A Prospective, Randomized, Multicenter Clinical Study Comparing Adjuvant Radiotherapy Versus Observation in High-risk Localized Adrenocortical Carcinoma After Surgery.Not yet recruitingNCT07141147Not applicable
• Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell LymphomaNot yet recruitingNCT07139353Phase 1/2
• EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal CarcinomaNot yet recruitingNCT07138989Phase 2
• Anlotinib Hydrochloride Capsules in Maintenance Treatment for Intermediate-High Risk Rhabdomyosarcoma in ChildrenNot yet recruitingNCT07137884Phase 2
• Iparomlimab and Tuvonralimab Combined With 2 or 4 Cycles of Chemotherapy as Neoadjuvant Therapy for Resectable NSCLCNot yet recruitingNCT07129161Phase 2
• Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell CarcinomaRecruitingNCT07125755Phase 3
• Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal CarcinomaNot yet recruitingNCT07110558Phase 2
• A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung CancerNot yet recruitingNCT07103408Phase 2
• A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung CancerRecruitingNCT07103395Phase 2
• Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical TrialRecruitingNCT07101744Phase 2
• Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell LymphomaRecruitingNCT07093710Phase 1/2
• Adaptive Chemotherapy for the Treatment of Advanced Breast CancerRecruitingNCT07088263Phase 3
• Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT07086469Phase 2
• Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung CancerRecruitingNCT07086456Phase 2
• Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B LymphomaRecruitingNCT07084662Phase 2/3
• Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell LymphomaRecruitingNCT07077512Phase 2
• Mechanism and Effect of Novel Metabolites on Valvular Heart DiseaseRecruitingNCT07065500
• Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal CarcinomaNot yet recruitingNCT07064902Phase 2
• The Real-world Study of AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)RecruitingNCT07064681
• A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTCNot yet recruitingNCT07062328Phase 2
• Human-AI Collaborative INSIGHT Diagnostic Workflow for in Breast Cancer With Extensive Intraductal ComponentNot yet recruitingNCT07060599Not applicable
• Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal CancerNot yet recruitingNCT07059338Phase 2
• Feasibility Study of Home Cardiac Rehabilitation Program for Postoperative Children With Congenital Heart DiseaseNot yet recruitingNCT07055347Not applicable
• Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLCRecruitingNCT07052669Phase 3
• Comparison of Endoscopy and Esophagram for the Routine Evaluation of Anastomosis After McKeown EsophagectomyRecruitingNCT07043491
• REal-world Data of CARdiometabolic ProtEcTionRecruitingNCT07038083

← Sun Yat-sen University overview and focus areas